Tumor-Associated Macrophages in Tumor Immunity.
Pan Y, Yu Y, Wang X, Zhang T. · 2020
Read Tumor-Associated Macrophages in Tumor Immunity. by Pan Y, Yu Y, Wang X, Zhang T. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7751482.txt.
Introduction
Pan and co-authors review tumor-associated macrophages and their role in tumor immunity. These macrophages are a main immune cell inside tumors. They fall into two broad states. M1 cells attack tumors direct. M2 cells help tumors grow, spread, and hide from T cells, and spur new blood vessels.
The two states are not fixed: cells can flip as conditions change. That flex makes these macrophages a tempting drug target. The review covers where they come from and how they talk with tumors. It sums up treatment plans that kill M2 cells or flip them to the M1 state. Timing and delivery remain the chief design problems.
Catalog record
| CREATOR | Pan Y, Yu Y, Wang X, Zhang T. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Tumor-Associated Macrophages in Tumor Immunity By Yueyun Pan, Yinda Yu, Xiaojian Wang, Ting Zhang Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2020.583084 ABSTRACT Abstract Tumor-associated macrophages (TAMs) represent one of the main tumor-infiltrating immune cell types and are generally categorized into either of two functionally contrasting subtypes, namely classical activated M1 macrophages and alternatively activated M2 macrophages. The former typically exerts anti-tumor functions, including directly mediate cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) to kill tumor cells; the latter can promote the occurrence and metastasis of tumor cells, inhibit T cell-mediated anti-tumor immune response, promote tumor angiogenesis, and lead to tumor progression. Both M1 and M2 macrophages have high degree of plasticity and thus can be converted into each other upon tumor microenvironment changes or therapeutic interventions. As the relationship between TAMs and malignant tumors becoming clearer, TAMs have become a promising target for developing new cancer treatment. In this review, we summarize the origin and types of TAMs, TAMs interaction with tumors and tumor microenvironment, and up-to-date treatment strategies targeting TAMs. Keywords: tumor-associated macrophages, regulation, immunosuppression, tumor microenvironment, tumor therapy INTRODUCTION Macrophages play critical roles in both innate and adaptive immunity and are known for their remarkable phenotypic heterogeneity and functional diversity. Embryonic hematopoietic stem cells in a variety of tissues during fetal development and differentiate into tissue-specific resident macrophages, including Kupffer cells in the liver, alveolar macrophages in the lung, and osteoclasts in bone tissue. After birth, bone marrow-derived precursors in particular circulating monocytes can also differentiate into macrophages in steady state or during tissue inflammation (1). Macrophages are involved in tissue and systemic inflammation and immunity, as well as tissue reconstruction. They have a wide range of functions, including phagocytosis, antigen presentation, defense against microbial cytotoxicity, and secretion of cytokines, complement components, etc. (2). It is worth noting that the broad biological activities of macrophages often have diametrically opposite characteristics, such as inflammatory response and anti-inflammatory activity; immunogenic and inducing immune tolerance; causing tissue destruction and repairing (3). Tumor-associated macrophages (TAMs) are macrophages that participate in the formation of the tumor microenvironment. TAMs are widely present in various tumors (4). TAMs can promote tumor growth, invasion, metastasis, and drug resistance (5). It has been proposed that functional difference of macrophages is closely related to the plasticity of macrophages, and its functional phenotype is regulated by molecules in tumor microenvironments. In this review, we discuss the origins and types of TAMs, the interaction between tumors and the tumor microenvironment, and review the emerging strategies for cancer treatment via targeting TAMs. ORIGINS AND TYPES OF TAMS Origins For a long period of time, it is believed that macrophages in tumors are exclusively recruited from the periphery by chemotaxis and generated by monocytic precursors in the local environment. However, more recent evidence shows that at least certain tumors, tissue-specific embryonic-derived resident macrophages infiltrate tumor tissues and thus represent a nonnegligible input source of TAMs (6). Although there have been studies showing that monocytic-derived but not embryonic-derived resident macrophages are capable in supporting the growing body of TAMs in the inflammatory environment of tumor, the potentially different roles of monocytic- versus embryonic-derived TAMs on tumor development and/or progress remains an intriguing question that is largely unanswered (2). M-MDSCs (monocyte-related myeloid-derived suppressor cells) are currently known as another main circulating precursor of TAMs. MDSCs are a type of myeloid leukocytes that is related to immunosuppression (7). Based on surface markers Ly6C+/Ly6C- and Ly6C-/Ly6G+, MDSCs can be divided into monocyte (M)-related and granulocyte (G)-related MDSC. Among them, M-MDSCs are induced into TAMs by various chemokines (8). It is all know that macrophages derive from bone marrow-derived monocytes. In tumors, TAMs mainly originate from bone marrow monocytes, but recent evidence suggests that, recruitment of circulating monocytes is essential for TAMs accumulation. Circulating inflammatory monocytes could be recruited by multiple chemokines (CCL2 and CCL5) and cytokines (CSF-1 and members of the VEGF family) to tumor (9). Tumor growth can also induce the differentiation of CCR2+ monocytes into TAMs (10). Furthermore, complement components, particularly C5a, are an important mediator of the recruitment and functional polarization of TAMs (11). Indeed, such chemokines do more than attractants do because they activate transcription programs that help macrophages tilt toward the functional of a particular phenotype (12). At the same time, CSF-1 is a monocyte attractant, as well as macrophage survival and polarization signals, which drive TAM to immunosuppressive differentiation M2 macrophages (13). Unlike CSF-1, GM-CSF activates macrophage function associated with antitumor activity (14). Types Macrophages undergo specific differentiation in different tissue environments, and can be divided into two different polarization states: M1 type macrophages (M1) and M2 type macrophages (M2). M1 can respond to dangerous signals transmitted by bacterial products or IFN-γ, which attracting and activating cells of the adaptive immune system; an important feature of M1 is that it can express nitric oxide synthase (iNOS) and reactive oxygen species (ROS) (15–17) and cytokine IL-12 (18). M1 also has the function of engulfing and killing target cells. M2 expresses a large number of scavenger receptors, which is related to the high-intensity expression of IL-10, IL-1β, VEGF and matrix metalloprotein (MMP) (19, 20). M2 has the function of removing debris, promoting angiogenesis, tissue reconstruction and injury repairments, as well as promoting tumorigenesis and development (4). It is worth noting that the polarization of macrophages into M2 appears to be oversimplified. Some people have classified M2 macrophages into M2a (induced by IL-4 or IL-13), M2b (induced by immune complexes combined with IL-1β or LPS) and M2c (induced by IL-10, TGFβ, or glucocorticoid), and M2d (conventional M2 macrophages that exert immunosuppression) (21, 22). THE ROLE OF TAMS IN TUMOR PROGRESS Current studies have shown that TAM population is in a state of constant transition between the two forms of M1 and M2 type. The proportion of each form is determined by the type and concentration of different signals in the tumor environment (Figure 1). [Figure: A schematic representation of the roles of tumor-associated macrophages (TAMs) in tumor progression. TAMs can mediate immune response, tumor cell proliferation and invasion, angiogenesis and metastasis. MMP, matrix metalloprotein; M-MDSCs, monocyte-related myeloid-derived suppressor cells; CSF1, macrophage colony-stimulating factor; VEGF, vascular endothelial growth factor; ROS, reactive oxygen species; INOS, nitric oxide synthases; LIF, leukocytosis induced factor.] M1 Macrophages and Tumor Suppression M1-type macrophages have anti-tumor effects, which can distinguish tumor cells from normal cells. By identifying tumor cells and ultimately killing tumor cells, studies have found that M1 type macrophages have two different effects on killing tumor cells mechanism. M1 type macrophages directly mediate cytotoxicity to kill tumor cells: macrophage-mediated cytotoxicity is a slow process (generally requires 1 to 3 days) and involves multiple mechanisms. For example, macrophages release tumor killing molecules such as ROS and NO, which have cytotoxic effects on tumor cells (23). The other is antibody-dependent cell-mediated cytotoxicity (ADCC) killing tumor cells: ADCC requires less time to kill tumor cells (generally within a few hours) and requires the participation of anti-tumor antibodies (24). M2 Macrophages Promote Tumor Cell Proliferation and Invasion TAM infiltration is closely related to tumor cell proliferation. Many studies have shown that TAMs can express a variety of cytokines that stimulate tumor cell proliferation and survival, including epithelial growth factor (EGF), platelet-derived growth factor